Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.
A three-pronged immunotherapy approach overcomes multiple immune barriers in prostate cancer, producing responses in patients who previously failed standard checkpoint therapy alone.
This NCI study reports durable responses to a rationally designed triplet immunotherapy combination addressing multiple immunosuppressive barriers in MMR-proficient castration-resistant prostate cancer. The approach simultaneously targets TGF-β immunosuppression, PD-L1 checkpoint, tumor antigen expression, and NK/T-cell activation via IL-15 superagonism, producing objective responses in a disease setting where checkpoint monotherapy has failed.
What the study was
- Study design
- Early-phase clinical trial (NCI-sponsored)
- Population
- Patients with mismatch repair-proficient castration-resistant prostate cancer
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
NCI early-phase trial of novel mechanistically rational triplet immunotherapy in MMR-proficient mCRPC — an immunotherapy-resistant disease. Combines TGF-β/PD-L1 inhibition (bintrafusp alfa), tumor antigen targeting, and IL-15 superagonist (ALT-803). Durable responses in this setting are highly significant.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.